Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
Cancer Chemotherapy and Pharmacology · 2023
DOI: 10.1007/s00280-023-04531-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Hidemi Nishi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Osaka University.
Abstract (Originalsprache)
Purpose
Although gemcitabine-based chemotherapy is most recommended for pancreatic ductal adenocarcinoma (PDAC), its effectiveness is limited because of drug resistance. Given thalidomide’s anti-tumor effects in solid tumors, we investigated the effect of avadomide, a novel thalidomide analog, on PDAC and explored its anti-tumor mechanisms.
Methods
PDAC cell lines, including gemcitabine-resistant (GR) clones derived from MiaPaCa2 cells, were used to evaluate the effects of avadomide. An annexin V assay, a cell cycle assay, and western blot analysis were performed to explain the mechanism of avadomide as an anti-tumor reagent. Moreover, we investigated the anti-tumor effect on tumor growth using a subcutaneous xenograft murine model.
Results
Avadomide showed anti-tumor effects in human PDAC cell lines. The proportion of apoptotic cells and G0/G1 phase cells after avadomide treatment increased, especially in the GR PDAC clones. Western blot analysis also showed the induction of the apoptotic pathway by inhibiting the NF-κB process and G1 phase cell cycle arrest. The xenograft murine model revealed that the proportion of viable cells in the avadomide-treated group was lower than that in the untreated group.
Conclusion
Our findings suggest that avadomide could be a novel therapeutic option to overcome gemcitabine resistance in patients with PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan. skobayashi@gesurg.med.osaka-u.ac.jp.
ORCID-Profile: Shogo Kobayashi
Förderung
- Osaka University
Zitieren
APA
Nishi, H., Gotoh, K., Tomimaru, Y., Kobayashi, S., Sasaki, K., Iwagami, Y., Yamada, D., Akita, H., Asaoka, T., Noda, T., Takahashi, H., Tanemura, M., Doki, Y., & Eguchi, H. (2023). Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04531-w
Vancouver
Nishi H, Gotoh K, Tomimaru Y, Kobayashi S, Sasaki K, Iwagami Y, et al. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04531-w
BibTeX
@article{Nishi2023,
author = {Nishi, Hidemi and Gotoh, Kunihito and Tomimaru, Yoshito and Kobayashi, Shogo and Sasaki, Kazuki and Iwagami, Yoshifumi and Yamada, Daisaku and Akita, Hirofumi and Asaoka, Tadafumi and Noda, Takehiro and Takahashi, Hidenori and Tanemura, Masahiro and Doki, Yuichiro and Eguchi, Hidetoshi},
title = {Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2023},
doi = {10.1007/s00280-023-04531-w}
}
EUVIMED